Pfizer Inc and BioNTech SE on Tuesday submitted initial trial data for their COVID-19 vaccine in five to 11-year-olds and said they would make a formal request to U.S. regulators for emergency use in the coming weeks.
The U.S. Food and Drug Administration said earlier this month it would look to complete its data review for this age group as quickly as possible, likely in a matter of weeks rather than months.
The companies, however, have yet to start the official process for authorization, which could slow the decision. According to the Wall Street Journal, the FDA may not make its decision until sometime between Halloween and Thanksgiving, citing a person familiar with the matter.
A Pfizer spokesperson said the company expects to start and complete its application very soon.
A decision on the vaccine’s use in younger children is eagerly awaited by millions of Americans as coronavirus infections have soared in children to the highest point in early September, according to data from the American Academy of Pediatrics.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.